HIND.US Vyome Holdings, Inc.

Healthcare Biotechnology USA Stocks
1.58 USD
Close of Nov 15, 2026
1.53 5.88
Market cap
USD 11.1M
P/E
0.9x
P/B
1.84x
ROE
-63.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HIND.US undervalued?

Graham number

The Graham number of Vyome Holdings, Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vyome Holdings, Inc. fundamental analysis

No fundamental analysis for Vyome Holdings, Inc. yet.

Vyome Holdings, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vyome Holdings, Inc.

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908,…

Full company profile